These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 12773033)

  • 1. A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one.
    Mylari BL; Armento SJ; Beebe DA; Conn EL; Coutcher JB; Dina MS; O'Gorman MT; Linhares MC; Martin WH; Oates PJ; Tess DA; Withbroe GJ; Zembrowski WJ
    J Med Chem; 2003 Jun; 46(12):2283-6. PubMed ID: 12773033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners.
    Mylari BL; Armento SJ; Beebe DA; Conn EL; Coutcher JB; Dina MS; O'Gorman MT; Linhares MC; Martin WH; Oates PJ; Tess DA; Withbroe GJ; Zembrowski WJ
    J Med Chem; 2005 Oct; 48(20):6326-39. PubMed ID: 16190759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat.
    Stribling D; Mirrlees DJ; Harrison HE; Earl DC
    Metabolism; 1985 Apr; 34(4):336-44. PubMed ID: 3920474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of potent aldose reductase inhibitors having a hydantoin structure.
    Miwa I; Hirano M; Inagaki K; Belbeoc'h C; Okuda J
    Biochem Pharmacol; 1987 Sep; 36(17):2789-94. PubMed ID: 3115267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners.
    Negoro T; Murata M; Ueda S; Fujitani B; Ono Y; Kuromiya A; Komiya M; Suzuki K; Matsumoto J
    J Med Chem; 1998 Oct; 41(21):4118-29. PubMed ID: 9767647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential aldose reductase inhibitors: 1,2,4-triazolidine-3,5-diones and 2-(3,4,5-trimethoxybenzoyl)-4,4-diethyl-3,5-isoxazolidinedione .
    Hall IH; Izydore RA; Simlot R; Wong OT
    Experientia; 1992 Apr; 48(4):383-6. PubMed ID: 1582496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel zwitterionic inhibitor of aldose reductase interferes with polyol pathway in ex vivo and in vivo models of diabetic complications.
    Karasova MJ; Prnova MS; Stefek M
    Pharmazie; 2014 Oct; 69(10):747-51. PubMed ID: 25985564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spiro hydantoin aldose reductase inhibitors.
    Sarges R; Schnur RC; Belletire JL; Peterson MJ
    J Med Chem; 1988 Jan; 31(1):230-43. PubMed ID: 3121857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
    Van Zandt MC; Jones ML; Gunn DE; Geraci LS; Jones JH; Sawicki DR; Sredy J; Jacot JL; Dicioccio AT; Petrova T; Mitschler A; Podjarny AD
    J Med Chem; 2005 May; 48(9):3141-52. PubMed ID: 15857120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of Ganoderma applanatum on rat lens aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues.
    Jung SH; Lee YS; Shim SH; Lee S; Shin KH; Kim JS; Kim YS; Kang SS
    Phytother Res; 2005 Jun; 19(6):477-80. PubMed ID: 16114079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoxazolo-[3,4-d]-pyridazin-7-(6H)-one as a potential substrate for new aldose reductase inhibitors.
    Costantino L; Rastelli G; Gamberini MC; Giovannoni MP; Dal Piaz V; Vianello P; Barlocco D
    J Med Chem; 1999 Jun; 42(11):1894-900. PubMed ID: 10354397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orally active aldose reductase inhibitors: indazoleacetic, oxopyridazineacetic, and oxopyridopyridazineacetic acid derivatives.
    Mylari BL; Zembrowski WJ; Beyer TA; Aldinger CE; Siegel TW
    J Med Chem; 1992 Jun; 35(12):2155-62. PubMed ID: 1613743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-substituted spirosuccinimide, spiropyridazine, spiroazetidine, and acetic acid aldose reductase inhibitors derived from isoquinoline-1,3-diones. 2.
    Malamas MS; Hohman TC
    J Med Chem; 1994 Jun; 37(13):2059-70. PubMed ID: 8027987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design synthesis and evaluation of novel aldose reductase inhibitors: The case of indolyl-sulfonyl-phenols.
    Koutsopoulos K; Lavrentaki V; Antoniou I; Kousaxidis A; Lefkopoulou M; Tsantili-Kakoulidou A; Kovacikova L; Stefek M; Nicolaou I
    Bioorg Med Chem; 2020 Aug; 28(15):115575. PubMed ID: 32631572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldose reductase inhibitors from Litchi chinensis Sonn.
    Lee SJ; Park WH; Park SD; Moon HI
    J Enzyme Inhib Med Chem; 2009 Aug; 24(4):957-9. PubMed ID: 19555177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners.
    Mylari BL; Beyer TA; Siegel TW
    J Med Chem; 1991 Mar; 34(3):1011-8. PubMed ID: 1900532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spiro hydantoin aldose reductase inhibitors derived from 8-aza-4-chromanones.
    Sarges R; Goldstein SW; Welch WM; Swindell AC; Siegel TW; Beyer TA
    J Med Chem; 1990 Jul; 33(7):1859-65. PubMed ID: 2113948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
    Mohd Siddique MU; Thakur A; Shilkar D; Yasmin S; Halakova D; Kovacikova L; Prnova MS; Stefek M; Acevedo O; Dasararaju G; Devadasan V; Mondal SK; Jayaprakash V
    Eur J Med Chem; 2021 Nov; 223():113630. PubMed ID: 34175538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
    Cameron NE; Cotter MA; Basso M; Hohman TC
    Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group.
    Steuber H; Zentgraf M; Podjarny A; Heine A; Klebe G
    J Mol Biol; 2006 Feb; 356(1):45-56. PubMed ID: 16337231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.